HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 31/4406 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 3, p. ex. zimeldine
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
An IL-15 super agonist (IL-15N72D:IL-15RαSU/IgG1Fc; N-803) increases circulating NK cells, effector memory and effector memory RA cells in post-allogeneic hematopoietic stem cell transplant patients (HCT). Methods of treatment include administration of N-803 to subjects in need of such treatment.
A61K 31/536 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes carbocycliques
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
Soluble fusion protein complexes, including domains from IL-15, IL-15 receptor, and αCTLA4 antibody for preventing, reducing the occurrence of, and/or treating cancer or an autoimmune disease or disorder in a subject are provided herein. The methods provided herein include administering to a subject a pharmaceutical composition of a soluble fusion protein complex.
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Compositions and methods are provided to treat and prevent cancers, such as myelomas, and include adoptive cell therapies in combination with an IL-15 superagonist and one or more chemotherapeutic agents.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A method of determining a clinical value for an individual based on a tumor in an image by an apparatus including processing circuitry may include executing, by the processing circuitry, instructions that cause the apparatus to determine a lymphocyte distribution of lymphocytes in the tumor based on the image; apply a classifier to the lymphocyte distribution to classify the tumor, the classifier having been trained to classify tumors into a class selected from at least two classes respectively associated with lymphocyte distributions; and determine the clinical value for the individual based on prognoses of individuals with tumors in the class into which the classifier classified the tumor.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
6.
Deep Learning Models For Region Of Interest Determination
A method of determining a region of interest in an image of tissue of an individual by an apparatus including processing circuitry may include executing, by the processing circuitry, instructions that cause the apparatus to partition an image of tissue of an individual into a set of areas, identify a tissue type of each area of the image, and apply a classifier to the image to determine a region of interest, the classifier being configured to determine regions of interest based on the tissue types of the set of areas of the image.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
8.
Production And Delivery Tracking And Sample Verification Of Patient-Specific Therapeutics
Systems and methods for tracking biological samples are presented. Intrinsic and extrinsic biological sample data and/or intrinsic and extrinsic patient data may be used to label a biological sample obtained at a point-of-care facility, which may be sent to a processing facility, wherein the labeled biological sample undergoes analysis and/or processing into a labeled therapeutic. The labeled therapeutic is delivered back to the point-of-care facility, wherein the labeled therapeutic is tested for the presence of the additives prior to administration to a patient. Multi-factor validation is performed, including validating the identity of the patient to a container, validating the identity of the labeled biological sample/therapeutic to the container, and thus, validating the identity of the labeled therapeutic to the patient. The entire life cycle of a biological sample used to generate a personalized therapeutic is validated, and ensures that mix-ups or errors in administration are reduced or eliminated.
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
An IL-15 super agonist (IL-15N72D:IL-15RαSU/IgGIFc; N-803) increases circulating NK cells, effector memory and effector memory RA cells in post-allogeneic hematopoietic stem cell transplant patients (HCT). Methods of treatment include administration of N-803 to subjects in need of such treatment.
A61K 31/536 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes carbocycliques
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
42 - Services scientifiques, technologiques et industriels, recherche et conception
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Providing online non-downloadable software featuring
information about medical providers, benefit investigation,
prior authorization processing, patient education, and
financial and co-pay assistance via an internet portal;
providing temporary use of online non-downloadable software
for allowing patients and customers of medical or health
services to access benefit investigation, prior
authorization processing, patient education, and financial
and co-pay assistance; providing temporary use of online
non-downloadable software for allowing a single location to
provide patient services to patients and customers of
medical or health services; providing temporary use of
online non-downloadable software for medical and healthcare
patients and customers that enables users to access and
monitor health and medical information and reports;
providing temporary use of online non-downloadable software
for medical and health hub services, namely, patient support
services, co-pay assistance, billing and account
receivables, shipping and reporting, patient data
aggregation and analysis, placing and tracking prescription
medication orders, tracking and analyzing patient clinical
care outcomes, receiving, processing, transmitting, and
displaying data, controlling and managing patient health
information, and medical and healthcare analytics; providing
temporary use of online non-downloadable software for a
centralized patient portal to permit the secure access of
patient information and to access, maintain, manage and
distribute patient medical information and other healthcare
information, and to facilitate communications, connectivity
and workflow with health care providers, healthcare
organizations and patients; providing temporary use of
online non-downloadable software for managing medical
information. Healthcare case management services, namely, administrative,
coordinative, and support services for medical providers,
insurers, and patients (term considered too vague by the
International Bureau - Rule 13 (2) (b) of the Regulations);
healthcare case management services, namely, administrative
and coordinative assistance in tracking patient treatment,
progress, concerns, and compliance issues, administrative
and support services in assisting patients with benefit
verification, administrative assistance to patients with
coverage confirmation, administrative assistance and support
services to patients with copayments, assistance and support
services to patients with reimbursements, and
administrative, coordinative, and support services in
relation to insurance plans and providers (term considered
too vague by the International Bureau - Rule 13 (2) (b) of
the Regulations).
11.
Object Storage And Access Management Systems And Methods
A geographically distributed erasure coding system includes multiple computer readable, non-transitory storage memories capable of storing a digital dataset including multiple object blocks, where each storage memory is configured to store one or more of the object blocks of the dataset according to an erasure coding policy. The system includes one or more processors configured to implement the erasure coding policy by distributing the multiple object blocks of the dataset to the multiple storage memories according to distribution criteria of the erasure coding policy, and the distribution criteria include at least one status parameter associated with each storage memory. The multiple storage memories are geographically distributed at different locations from one another.
G06F 3/06 - Entrée numérique à partir de, ou sortie numérique vers des supports d'enregistrement
G06F 21/62 - Protection de l’accès à des données via une plate-forme, p. ex. par clés ou règles de contrôle de l’accès
H03M 13/15 - Codes cycliques, c.-à-d. décalages cycliques de mots de code produisant d'autres mots de code, p. ex. codes définis par un générateur polynomial, codes de Bose-Chaudhuri-Hocquenghen [BCH]
12.
Modified T Cell Receptors For The Prevention And Treatment Of Viral Infections And Cancer
Modified T cell receptors, cells comprising the modified T cell receptors, nucleic acids encoding the modified T cell receptors, and methods for using the modified T cell receptors are contemplated. Modified T cell receptor comprising two peptide chains are disclosed herein. The two peptide chains may be the same or different, and each peptide chain comprises an extracellular domain comprising a variable region, a constant region, and a connecting peptide, a transmembrane domain, and an intracellular domain comprising a CD28 region and a CD3 ξ ITAM region. Nucleic acids encoding the modified T cell receptors, and vectors comprising the nucleic acids are also disclosed. Additionally, a method for treating cancer and/or a viral infection is disclosed comprising administering a cell comprising the modified T cell receptor.
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
An apparatus for electroporating cells with a cargo includes electrodes defining a path for a fluid including the cells and the cargo to flow, a power source coupled across the electrodes, and a control circuit. In some examples, the control circuit is configured to detect a decrease in an induced current due to an increase in a resistance between the electrodes, and control the power source to increase the induced current to maintain an electric field between the electrodes. A future value of the resistance between the electrodes may be predicted based on previous values of the resistance. In other examples, the control circuit is configured to detect parameters of the fluid flowing between the electrodes, and control the power source to generate or stop generating electrical pulses in response to detecting the parameters. Other example apparatuses, and methods of electroporating cells with a cargo is also disclosed.
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation
A61N 1/08 - Aménagements ou circuits de surveillance, de protection, de commande ou d'indication
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
An example system for performing segmentation of data based on tensor inputs includes memory storing computer-executable instructions defining a learning network, where the learning network includes a plurality of sequential encoder down-sampling blocks. A processor is configured to execute the computer-executable instructions to receive a multi-dimensional input tensor including at least a first dimension, a second dimension and a plurality of channels. The processor is also configured to process the received multi-dimensional input tensor by passing the received multi-dimensional input tensor through the plurality of sequential encoder down-sampling blocks of the learning network, and to generate an output tensor in response to processing the received multi-dimensional input tensor. The output tensor includes at least one segmentation classification.
G06F 18/21 - Conception ou mise en place de systèmes ou de techniquesExtraction de caractéristiques dans l'espace des caractéristiquesSéparation aveugle de sources
G06F 18/211 - Sélection du sous-ensemble de caractéristiques le plus significatif
G06F 18/241 - Techniques de classification relatives au modèle de classification, p. ex. approches paramétriques ou non paramétriques
A method of determining a region of interest in an image of tissue of an individual by an apparatus including processing circuitry may include executing, by the processing circuitry, instructions that cause the apparatus to partition an image of tissue of an individual into a set of areas, identify a tissue type of each area of the image, and apply a classifier to the image to determine a region of interest, the classifier being configured to determine regions of interest based on the tissue types of the set of areas of the image.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
(1) Providing online non-downloadable software featuring information about medical providers, benefit investigation, prior authorization processing, patient education, and financial and co-pay assistance via an internet portal; providing temporary use of online non-downloadable software for allowing patients and customers of medical or health services to access benefit investigation, prior authorization processing, patient education, and financial and co-pay assistance; providing temporary use of online non-downloadable software for allowing a single location to provide patient services to patients and customers of medical or health services; providing temporary use of online non-downloadable software for medical and healthcare patients and customers that enables users to access and monitor health and medical information and reports; providing temporary use of online non-downloadable software for medical and health hub services, namely, patient support services, co-pay assistance, billing and account receivables, shipping and reporting, patient data aggregation and analysis, placing and tracking prescription medication orders, tracking and analyzing patient clinical care outcomes, receiving, processing, transmitting, and displaying data, controlling and managing patient health information, and medical and healthcare analytics; providing temporary use of online non-downloadable software for a centralized patient portal to permit the secure access of patient information and to access, maintain, manage and distribute patient medical information and other healthcare information, and to facilitate communications, connectivity and workflow with health care providers, healthcare organizations and patients; providing temporary use of online non-downloadable software for managing medical information.
(2) Healthcare case management services, namely, administrative, coordinative, and support services for medical providers, insurers, and patients (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); healthcare case management services, namely, administrative and coordinative assistance in tracking patient treatment, progress, concerns, and compliance issues, administrative and support services in assisting patients with benefit verification, administrative assistance to patients with coverage confirmation, administrative assistance and support services to patients with copayments, assistance and support services to patients with reimbursements, and administrative, coordinative, and support services in relation to insurance plans and providers (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations).
18.
Production and delivery tracking and sample verification of patient-specific therapeutics
Systems and methods for tracking biological samples are presented. Intrinsic and extrinsic biological sample data and/or intrinsic and extrinsic patient data may be used to label a biological sample obtained at a point-of-care facility, which may be sent to a processing facility, wherein the labeled biological sample undergoes analysis and/or processing into a labeled therapeutic. The labeled therapeutic is delivered back to the point-of-care facility, wherein the labeled therapeutic is tested for the presence of the additives prior to administration to a patient. Multi-factor validation is performed, including validating the identity of the patient to a container, validating the identity of the labeled biological sample/therapeutic to the container, and thus, validating the identity of the labeled therapeutic to the patient. The entire life cycle of a biological sample used to generate a personalized therapeutic is validated, and ensures that mix-ups or errors in administration are reduced or eliminated.
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
19.
Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
20.
PEPTIDE THERAPEUTICS AGAINST SARS-COV-2 SPIKE PROTEIN
Proteinaceous therapeutics, such as antibodies and fusion proteins, for preventing, reducing the occurrence of, and/or treating a SARS-CoV-2 infection in a subject are provided herein. The methods provided herein include administering to a subject an antigen binding fragments (Fab fragment) or antibody that binds to the SARS-CoV-2 Spike protein, and/or a DNA construct encoding an anti-Spike Fab fragment.
Systems and methods for tracking biological samples are presented. In some embodiments, intrinsic and extrinsic biological sample data and/or intrinsic and extrinsic patient data are used to label a biological sample obtained at a point-of-care facility. The labeled biological sample may be sent to a processing facility, wherein the labeled biological sample undergoes analysis and/or processing into a labeled therapeutic. The labeled therapeutic is delivered back to the point-of-care facility, wherein the labeled therapeutic is tested for the presence of the additives prior to administration to a patient. Multi-factor validation is performed, including validating the identity of the patient to a container, validating the identity of the labeled biological sample/therapeutic to the container, and thus, validating the identity of the labeled therapeutic to the patient. The entire life cycle of a biological sample used to generate a personalized therapeutic is validated, and ensures that mix-ups or errors in administration are reduced or eliminated.
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate recombinant nucleic acids that encode one or more polytopes that are optimized for proper trafficking and processing. In preferred methods, the polytopes are encoded in a plasmid and/or a viral expression system for use as a therapeutic agent.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 31/431 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes contenant d'autres systèmes hétérocycliques, p. ex. ticarcilline, azlocilline, oxacilline
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 31/14 - Antiviraux pour le traitement des virus ARN
HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 31/4406 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 3, p. ex. zimeldine
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
Disclosed systems and methods include executing a convolutional neural network to detect a level of microbiome in a whole slide image associated with a patient, based on an output of the convolutional neural network, categorize the whole slide image as one of microbiome-low and microbiome-high, and, based on the categorization of the whole slide image, determine a characteristic of a cancer associated with the patient.
Disclosed systems and methods include executing a convolutional neural network to detect a level of microbiome in a whole slide image associated with a patient, based on an output of the convolutional neural network, categorize the whole slide image as one of microbiome-low and microbiome-high, and, based on the categorization of the whole slide image, determine a characteristic of a cancer associated with the patient.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Providing a website and online non-downloadable Internet-based software application featuring technology which allows for the managing of information about a customer's medical and health services, including information about medical providers, benefit investigation, prior authorization processing, patient education, and financial and co-pay assistance; Providing temporary use of online non-downloadable software for allowing patients and customers of medical or health services to access benefit investigation, prior authorization processing, patient education, and financial and co-pay assistance; Providing temporary use of online non-downloadable software for allowing a single location to provide patient services to patients and customers of medical or health services; Providing temporary use of online non-downloadable software for medical and healthcare patients and customers that enables users to access and monitor health and medical information and reports; Providing temporary use of online non-downloadable software for medical and health services, namely, patient support services, co-pay assistance, billing and account receivables, shipping and reporting, patient data aggregation and analysis, placing and tracking prescription medication orders, tracking and analyzing patient clinical care outcomes, receiving, processing, transmitting, and displaying data, controlling and managing patient health information, and medical and healthcare analytics; Providing temporary use of online non-downloadable software for a centralized patient portal to permit the secure access of patient information and to access, maintain, manage and distribute patient medical information and other healthcare information, and to facilitate communications, connectivity and workflow with health care providers, healthcare organizations and patients; Providing temporary use of online non-downloadable software for managing medical information
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Healthcare case management services, namely, coordination of services among medical providers, insurers, and patients; healthcare case management services, namely, tracking patient treatment, progress, concerns, and compliance issues, assisting patients with benefit verification, assisting patients with coverage confirmation, assistance with copayments, assistance with deductibles, assistance with reimbursements, and communications with insurance plans and providers
Vaccine compositions are provided that comprise a lyophilized, adenovirus-based expression vector, and a stabilizing compound, such as such as aragonite. Further provided are compositions that include a solid dosage form made from aragonite for loading and delivery of a vaccine composition.
An IL-15 super agonist (IL-15N72D:IL-15RαSU/IgG1Fc; N-803) increases circulating NK cells, effector memory and effector memory RA cells in post-allogeneic hematopoietic stem cell transplant patients (HCT). Methods of treatment include administration of N-803 to subjects in need of such treatment.
A61K 31/536 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes carbocycliques
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
31.
Computerized Tool For Prediction of Proteasomal Cleavage
A method of preparing a vaccine includes providing an immune epitope database; providing a neural network; receiving data corresponding to at least one protein into the neural network; receiving data corresponding to one or more candidate peptides corresponding to potential cleavage products of the at least one protein, or determining, using the neural network, data corresponding to one or more candidate peptides corresponding to potential cleavage products of the at least one protein; calculating, using the neural network, a probability of cleavage of the protein to result in each of the one or more candidate peptides; and outputting a signal corresponding to the calculated probability. An architecture having two channel output, i.e., output of a C-terminal cleavage and an N-terminal cleavage, is described. Related devices, apparatuses, systems, techniques, articles and non-transitory computer-readable storage medium are also described.
Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid protein
Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
Provided herein, are methods and compositions for detecting heteromeric protein complexes in biological samples. The methods and compositions allow for capturing and detecting the protein complex with substantially the same antibody, while avoiding detection of native proteins.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
Soluble fusion protein complexes, including domains from IL-15, IL-15 receptor, and αCTLA4 antibody for preventing, reducing the occurrence of, and/or treating cancer or an autoimmune disease or disorder in a subject are provided herein. The methods provided herein include administering to a subject a pharmaceutical composition of a soluble fusion protein complex.
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Compositions and methods are presented that allow for detection and prediction of an immune response in a subject that is selected to receive or that has received a vaccine. In selected embodiments, whole blood is used as starting material to obtain both dendritic cells and T cells, and synthetic or recombinant polypeptide(s) are used that include an antigen of the vaccine. The dendritic cells are then exposed to the synthetic or recombinant polypeptide(s), and thusly exposed dendritic cells are combined with the T cells to generate antigen reactive T cells. For detection or quantification, the antigen reactive T cells are expanded in vitro prior to ELISPOT or FACS analysis. Advantageously, such systems and methods are especially suitable for ascertaining an immune response against cancer antigens following vaccination with an anti-cancer vaccine.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Soluble fusion protein complexes, including domains from IL-15, IL-15 receptor, and αCTLA4 antibody for preventing, reducing the occurrence of, and/or treating cancer or an autoimmune disease or disorder in a subject are provided herein. The methods provided herein include administering to a subject a pharmaceutical composition comprising the soluble fusion protein complex.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
37.
Object storage and access management systems and methods
A geographically distributed erasure coding system includes multiple computer readable, non-transitory storage memories capable of storing a digital dataset including multiple object blocks, where each storage memory is configured to store one or more of the object blocks of the dataset according to an erasure coding policy. The system includes one or more processors configured to implement the erasure coding policy by distributing the multiple object blocks of the dataset to the multiple storage memories according to distribution criteria of the erasure coding policy, and the distribution criteria include at least one status parameter associated with each storage memory. The multiple storage memories are geographically distributed at different locations from one another.
G06F 3/06 - Entrée numérique à partir de, ou sortie numérique vers des supports d'enregistrement
G06F 21/62 - Protection de l’accès à des données via une plate-forme, p. ex. par clés ou règles de contrôle de l’accès
H03M 13/15 - Codes cycliques, c.-à-d. décalages cycliques de mots de code produisant d'autres mots de code, p. ex. codes définis par un générateur polynomial, codes de Bose-Chaudhuri-Hocquenghen [BCH]
38.
Peptide Therapeutics Against SARS-COV-2 Spike Protein
Proteinaceous therapeutics, such as antibodies and fusion proteins, for preventing, reducing the occurrence of, and/or treating a SARS-CoV-2 infection in a subject are provided herein. The methods provided herein include administering to a subject an antigen binding fragments (Fab fragment) or antibody that binds to the S ARS-CoV-2 Spike protein, ACE2 decoy peptides that bind to the SAILS-CoV-2 Spike protein, and/or a DNA construct encoding an anti-Spike Fab fragment or ACE2 decoy peptide.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations and substances for the treatment
of human diseases, animal diseases, autoimmune diseases,
infectious diseases and cancer for scientific, clinical,
medicinal, therapeutic, and diagnostic purposes;
pharmaceutical preparations and substances for the
prevention, diagnosis, and treatment of human diseases,
animal diseases, autoimmune diseases, infectious diseases
and cancer; pharmaceutical and biological preparations for
use in targeted immunotherapy for the treatment of human
diseases, animal diseases, autoimmune diseases, infectious
diseases and cancer; biological preparations for medical
purposes, namely, in the field of vaccines; pharmaceutical
preparations for low-dose chemotherapies, low dose radiation
therapies, and personalized neoepitope-targeted therapies
for medical use for the treatment of human diseases, animal
diseases, autoimmune diseases, infectious diseases, and
cancer; anti-cancer preparations; vaccines; biologics,
namely, cell-derived preparations, pharmaceutical
preparations for cell therapies, monoclonal antibodies,
cytokines, immune modulators, pharmaceutical preparations
for low-dose chemotherapy and low-dose radiation therapy,
antibodies, fusion proteins, peptide and cytokine biologics,
vaccines, pharmaceutical preparations for personalized
neoepitope-based therapies and cell therapies, and natural
killer cell derived preparations for clinical, medicinal,
therapeutic, and veterinary purposes; kits for clinical,
medicinal, therapeutic, and veterinary purposes featuring
cell cultures, and reagents. Medical and pharmaceutical research and development
services; medical and scientific research in the fields of
pharmaceuticals, oncology, immune-oncology, immunotherapy,
human diseases, animal diseases, cancer, vaccines,
autoimmune diseases, and infectious diseases; product
development in the fields of pharmaceuticals, oncology,
immune-oncology, immunotherapy, human diseases, animal
diseases, cancer, vaccines, autoimmune diseases, and
infectious diseases. Medical services; medical information; providing medical
information in the fields of immunotherapy via a website;
providing medical information in the fields of human
diseases, animal diseases, cancer, vaccines, autoimmune
diseases, and infectious diseases via a website; providing
information relating to pharmaceuticals, oncology,
immune-oncology, immunotherapy, human diseases, animal
diseases, cancer, vaccines, autoimmune diseases, infectious
diseases, biologics, cells, and cell-derived preparations.
40.
Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
41.
RAPID VERIFICATION OF VIRUS PARTICLE PRODUCTION FOR A PERSONALIZED VACCINE
Methods for rapidly confirming production of infectious viral vectors, for use in clinical grade personalized neo-antigen vaccines for subjects in need thereof, are provided.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ prime-boost vaccination in combination with immune modulatory treatment and biasing of an immune response towards a Th1 profile.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Pharmaceutical preparations and substances for the treatment of human diseases, animal diseases, autoimmune diseases, infectious diseases and cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations and substances for the prevention, diagnosis, and treatment of human diseases, animal diseases, autoimmune diseases, infectious diseases and cancer; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment of human diseases, animal diseases, autoimmune diseases, infectious diseases and cancer; biological preparations for medical purposes, namely, in the field of vaccines; pharmaceutical preparations for low-dose chemotherapies, low dose radiation therapies, and personalized neoepitope-targeted therapies for medical use for the treatment of human diseases, animal diseases, autoimmune diseases, infectious diseases, and cancer; anti-cancer preparations; vaccines; biologics, namely, cell-derived preparations, pharmaceutical preparations for cell therapies, monoclonal antibodies, cytokines, immune modulators, pharmaceutical preparations for low-dose chemotherapy and low-dose radiation therapy, antibodies, fusion proteins, peptide and cytokine biologics, vaccines, pharmaceutical preparations for personalized neoepitope-based therapies and cell therapies, and natural killer cell derived preparations for clinical, medicinal, therapeutic, and veterinary purposes; kits for clinical, medicinal, therapeutic, and veterinary purposes featuring cell cultures, and reagents. (1) Medical services; medical information; providing medical information in the fields of immunotherapy via a website; providing medical information in the fields of human diseases, animal diseases, cancer, vaccines, autoimmune diseases, and infectious diseases via a website; providing information relating to pharmaceuticals, oncology, immune-oncology, immunotherapy, human diseases, animal diseases, cancer, vaccines, autoimmune diseases, infectious diseases, biologics, cells, and cell-derived preparations.
(2) Medical and pharmaceutical research and development services; medical and scientific research in the fields of pharmaceuticals, oncology, immune-oncology, immunotherapy, human diseases, animal diseases, cancer, vaccines, autoimmune diseases, and infectious diseases; product development in the fields of pharmaceuticals, oncology, immune-oncology, immunotherapy, human diseases, animal diseases, cancer, vaccines, autoimmune diseases, and infectious diseases
A method of determining a clinical value for an individual based on a tumor in an image by an apparatus including processing circuitry may include executing, by the processing circuitry, instructions that cause the apparatus to determine a lymphocyte distribution of lymphocytes in the tumor based on the image; apply a classifier to the lymphocyte distribution to classify the tumor, the classifier having been trained to classify tumors into a class selected from at least two classes respectively associated with lymphocyte distributions; and determine the clinical value for the individual based on prognoses of individuals with tumors in the class into which the classifier classified the tumor.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G06F 18/2413 - Techniques de classification relatives au modèle de classification, p. ex. approches paramétriques ou non paramétriques basées sur les distances des motifs d'entraînement ou de référence
Modified T cell receptors, cells comprising the modified T cell receptors, nucleic acids encoding the modified T cell receptors, and methods for using the modified T cell receptors are contemplated. Modified T cell receptor comprising two peptide chains are disclosed herein. The two peptide chains may be the same or different, and each peptide chain comprises an extracellular domain comprising a variable region, a constant region, and a connecting peptide, a transmembrane domain, and an intracellular domain comprising a CD28 region and a CD3 ζ ITAM region. Nucleic acids encoding the modified T cell receptors, and vectors comprising the nucleic acids are also disclosed. Additionally, a method for treating cancer and/or a viral infection is disclosed comprising administering a cell comprising the modified T cell receptor.
Multimodal cancer immunotherapy is a combination of cancer immunotherapies used to treat cancer in patients. T cell receptor diversity is used as a component of a method to treat cancer involving cancer therapy, including multimodal cancer immunotherapy.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
Contemplated cancer therapies comprise co-administration of aldoxorubicin with an immune therapeutic composition that preferably comprises a vaccine component and a cytotoxic cell component.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
48.
RAPID TEST FOR PATIENT CD8 T-CELL ACTIVATION, SYSTEMS AND METHODS
Systems and methods are provided wherein patient derived whole blood is assayed for disease-specific CD8 T cell activity. Viral and cancer antigen induced CD8 T cell cytotoxicity is elicited by disease specific peptides.
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
49.
Deep learning models for region-of-interest determination
A method of determining a region of interest in an image of tissue of an individual by an apparatus including processing circuitry may include executing, by the processing circuitry, instructions that cause the apparatus to partition an image of tissue of an individual into a set of areas, identify a tissue type of each area of the image, and apply a classifier to the image to determine a region of interest, the classifier being configured to determine regions of interest based on the tissue types of the set of areas of the image.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Medical services; medical information; providing a website featuring medical information in the fields of immunotherapy; providing a website featuring medical information in the fields of human diseases, animal diseases, cancer, vaccines, autoimmune diseases, and infectious diseases; providing information relating to pharmaceuticals, oncology, immune-oncology, immunotherapy, human diseases, animal diseases, cancer, vaccines, autoimmune diseases, infectious diseases, biologics, cells, and cell-derived preparations
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations and substances for the treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases and cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations and substances for the prevention, diagnosis, and treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases and cancer; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases and cancer; biological preparations for medical purposes, namely, vaccines for human use and animal use; low-dose chemotherapies, low dose radiation therapies, and personalized neoepitope-targeted therapies, all of the foregoing in the nature of pharmaceutical preparations for medical use for the treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases, and cancer; anti-cancer preparations; vaccines; biologics, namely, cell-derived preparations, cell therapies, monoclonal antibodies, cytokines, immune modulators, low-dose chemotherapy, low-dose radiation therapy, antibodies, fusion proteins, peptide and cytokine biologics, vaccines, personalized neoepitope-based therapies, cell therapies, and natural killer cell derived preparations, all of the foregoing in the nature of pharmaceutical preparations for clinical, medicinal, therapeutic, and veterinary purposes for the prevention, diagnosis, and treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases and cancer; kits for clinical, medicinal, therapeutic, and veterinary purposes comprised of clinical medical reagents, cell cultures media for laboratory use, and related printer user instructions sheets
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Medical and pharmaceutical research and development services; medical and scientific research in the fields of pharmaceuticals, oncology, immune-oncology, immunotherapy, human diseases, animal diseases, cancer, vaccines, autoimmune diseases, and infectious diseases; product development in the fields of pharmaceuticals, oncology, immune-oncology, immunotherapy, human diseases, animal diseases, cancer, vaccines, autoimmune diseases, and infectious diseases
53.
Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Compositions and methods are provided to treat and prevent cancers, such as myelomas, and include adoptive cell therapies in combination with an IL-15 superagonist and one or more chemotherapeutic agents.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.
Techniques are provided for determining pan-HLA binding of viral proteins. A trained classifier model is operable to determine, independently per HLA, at least one of (a) an average binding prediction of overlapping peptides at each position of a viral protein, (b) a maximum value of a binding prediction of overlapping peptides at each position of the viral protein, (c) standard deviation of a binding prediction of overlapping peptides at each position of the viral protein, and (d) a combination of one or more of (a)-(c). A classification engine uses the classifier model to determine average binding predictions of overlapping peptides at each position of the viral protein independently for test HLA-I and HLA-II functional groupings, where a peptide is classified as a binder when an average binding prediction corresponding to the peptide satisfies a binding value threshold.
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Methods for detecting the presence of sever acute respiratory coronavirus 2 (SARS-CoV-2) are provided. The methods comprise incubating a sample comprising T-cells from an individual with one or more SARS-CoV-2 antigens, each antigen having a T-cell epitope, and detecting a change in state of T-cells in the sample. The change in state may be detected by determining the presence or level of a secreted, immune response indicator, such as interferon-gamma (IFN-γ).
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.
Disclosed are therapeutic compositions for the prevention, amelioration and/or treatment of infectious disease, including, but not limited to, SARS-COV2.
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. clothiapine, diltiazem
A61P 31/14 - Antiviraux pour le traitement des virus ARN
61.
IL-15 agonist drug combinations for immune therapy
Methods and pharmaceutical combinations for preventing, reducing the occurrence of, and/or treating an infection in a subject are provided herein. The method includes administering to the subject a therapeutically effective amount of an IL-15 agonist after or concomitantly with administration of a therapeutically effective amount of an antibiotic to the subject. The pharmaceutical combination includes an IL-15 agonist and an antibiotic.
A61K 31/545 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine
A61K 31/546 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine contenant d'autres hétérocycles, p. ex. céphalotine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
62.
PHARMACEUTICAL COMPOSITIONS TO ENHANCE PHAGOCYTOSIS WITHOUT INFLAMMATION
The invention relates to a composition comprising a peptide and an immunotherapeutic composition, and a method of inducing phagocytosis without inflammation comprising administering the composition.
Vaccine compositions are provided that comprise a lyophilized, adenovirus-based expression vector, and a stabilizing compound, such as such as aragonite. Further provided are compositions that include a solid dosage form made from aragonite for loading and delivery of a vaccine composition.
A method for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a sample is provided. The method includes contacting at least two pairs of primers with a complementary deoxyribonucleic acid (cDNA) derived from SARS-CoV-2 ribonucleic acid (RNA) in the sample; amplifying a portion of the cDNA by quantitative loop-mediated isothermal amplification (qLAMP) in the presence of a marker that exhibits a detectable signal as the cDNA is amplified, wherein the portion of the cDNA comprises a portion of non-structural protein 3 (Nsp3)-gene cDNA, a portion of S-gene cDNA, a portion of a 3′ end of N-gene cDNA, or combinations thereof; periodically measuring the detectable signal during the isothermally amplifying; and determining at least one of an amplification threshold breach or an amplification rate corresponding to levels of the detectable signal versus amplification time. Treatment methods, reaction mixtures, and assay kits are also provided.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
65.
Waveform Analysis And Detection Using Machine Learning Transformer Models
A computerized method of analyzing a waveform using a machine learning transformer model includes obtaining labeled waveform training data and unlabeled waveform training data, supplying the unlabeled waveform training data to the transformer model to pre-train the transformer model by masking a portion of an input to the transformer model, and supplying the labeled waveform training data to the transformer model without masking a portion of the input to the transformer model to fine-tune the transformer model. Each waveform in the labeled waveform training data includes at least one label identifying a feature of the waveform. The method also includes supplying a target waveform to the transformer model to classify at least one feature of the target waveform. The at least one classified feature corresponds to the least one label of the labeled waveform training data.
An apparatus for electroporating cells with a cargo includes electrodes defining a path for a fluid including the cells and the cargo to flow, a power source coupled across the electrodes, and a control circuit. In some examples, the control circuit is configured to detect a decrease in an induced current due to an increase in a resistance between the electrodes, and control the power source to increase the induced current to maintain an electric field between the electrodes. A future value of the resistance between the electrodes may be predicted based on previous values of the resistance. In other examples, the control circuit is configured to detect parameters of the fluid flowing between the electrodes, and control the power source to generate or stop generating electrical pulses in response to detecting the parameters. Other example apparatuses, and methods of electroporating cells with a cargo is also disclosed.
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
A61N 1/08 - Aménagements ou circuits de surveillance, de protection, de commande ou d'indication
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation
An apparatus for electroporating cells with a cargo includes electrodes defining a path for a fluid including the cells and the cargo to flow, a power source coupled across the electrodes, and a control circuit. In some examples, the control circuit is configured to detect a decrease in an induced current due to an increase in a resistance between the electrodes, and control the power source to increase the induced current to maintain an electric field between the electrodes. A future value of the resistance between the electrodes may be predicted based on previous values of the resistance. In other examples, the control circuit is configured to detect parameters of the fluid flowing between the electrodes, and control the power source to generate or stop generating electrical pulses in response to detecting the parameters. Other example apparatuses, and methods of electroporating cells with a cargo are also disclosed.
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
C12M 1/36 - Appareillage pour l'enzymologie ou la microbiologie comportant une commande sensible au temps ou aux conditions du milieu, p. ex. fermenteurs commandés automatiquement
68.
Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
Disclosed herein are methods for inducing immunity against a severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV2) in a patient in need thereof. The method comprises administering a vaccine composition comprising a self-adjuvanted SARS-CoV2 Spike (S) RNA-based vaccine (AAHI-SC2), followed by administering a replication defective adenovirus (hAd5) vaccine composition, wherein the adenovirus comprises an E1 gene region deletion and an E2b gene region deletion.
HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/4406 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 3, p. ex. zimeldine
A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
A geographically distributed erasure coding system includes multiple computer readable, non-transitory storage memories capable of storing a digital dataset including multiple object blocks, where each storage memory is configured to store one or more of the object blocks of the dataset according to an erasure coding policy. The system includes one or more processors configured to implement the erasure coding policy by distributing the multiple object blocks of the dataset to the multiple storage memories according to distribution criteria of the erasure coding policy, and the distribution criteria include at least one status parameter associated with each storage memory. The multiple storage memories are geographically distributed at different locations from one another.
G06F 3/06 - Entrée numérique à partir de, ou sortie numérique vers des supports d'enregistrement
H03M 13/15 - Codes cycliques, c.-à-d. décalages cycliques de mots de code produisant d'autres mots de code, p. ex. codes définis par un générateur polynomial, codes de Bose-Chaudhuri-Hocquenghen [BCH]
G06F 21/62 - Protection de l’accès à des données via une plate-forme, p. ex. par clés ou règles de contrôle de l’accès
An EL-15 super agonist (IL-15N72D:IL-15RαSU/IgG1Fc; N-803) increases circulating NK cells, effector memory and effector memory RA cells in post-allogeneic hematopoietic stem cell transplant patients (HCT). Methods of treatment include administration of N-803 to subjects in need of such treatment.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 31/536 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes carbocycliques
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
Proteinaceous therapeutics, such as antibodies and fusion proteins, for preventing, reducing the occurrence of, and/or treating a SARS-CoV-2 infection in a subject are provided herein. The methods provided herein include administering to a subject a therapeutically effective amount of an antigen binding fragments (Fab fragment) or antibody that binds to the SARS-CoV-2 Spike protein, ACE2 decoy peptides that bind to the SARS-CoV-2 Spike protein, and/or a DNA construct encoding an anti-Spike Fab fragment or ACE2 decoy peptide.
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
C12N 9/48 - Hydrolases (3.) agissant sur les liaisons peptidiques, p. ex. thromboplastine, aminopeptidase de la leucine (3.4)
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
73.
Replication-defective adenoviruses comprising nucleic acids encoding SARS-CoV-2 s glycoprotein and modified N protein comprising an endosomal targeting sequence
Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
Ex vivo determination of increased tumor immunogenicity of a tumor biopsy is used as a guide to identify immunotherapy of a tumor in a patient. Most preferably, the ex vivo tests will include exposure of biopsy samples to stress conditions to produce pretreated tumor cells that are then assayed with immune competent cells for increased activation or activity. Test conditions include exposure of the biopsy samples to immune stimulatory compositions, antibodies against neoepitopes, and/or modified cells, and an increase of immunogenicity is preferably determined by their exposure to T cells and/or NK cells.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A method of determining a clinical value for an individual based on a tumor in an image by an apparatus including processing circuitry may include executing, by the processing circuitry, instructions that cause the apparatus to determine a lymphocyte distribution of lymphocytes in the tumor based on the image; apply a classifier to the lymphocyte distribution to classify the tumor, the classifier having been trained to classify tumors into a class selected from at least two classes respectively associated with lymphocyte distributions; and determine the clinical value for the individual based on prognoses of individuals with tumors in the class into which the classifier classified the tumor.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
G16H 80/00 - TIC spécialement adaptées pour faciliter la communication entre les professionnels de la santé ou les patients, p. ex. pour le diagnostic collaboratif, la thérapie collaborative ou la surveillance collaborative de l’état de santé
Pancytopenia, in particular lymphopenia is treated with compositions which include an IL-15 superagonist, IL-15, an IL-15 mutant, IL-15: IL-15 receptor alpha (IL-15Ra) complex or combinations thereof. Administration of preferred compositions results in the increase of blood cells, in particular, lymphocytes in subjects in need of such treatment. In one aspect, methods and compositions are provided to prevent and/or treat a subject suffering from or susceptible to pancytopenia..
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ prime-boost vaccination in combination with immune modulatory treatment and biasing of an immune response towards a Th1 profile.
An example system for performing segmentation of data based on tensor inputs includes memory storing computer-executable instructions defining a learning network, where the learning network includes a plurality of sequential encoder down-sampling blocks. A processor is configured to execute the computer-executable instructions to receive a multi-dimensional input tensor including at least a first dimension, a second dimension and a plurality of channels. The processor is also configured to process the received multi-dimensional input tensor by passing the received multi-dimensional input tensor through the plurality of sequential encoder down-sampling blocks of the learning network, and to generate an output tensor in response to processing the received multi-dimensional input tensor. The output tensor includes at least one segmentation classification.
An example system for performing segmentation of data based on tensor inputs includes memory storing computer-executable instructions defining a learning network, where the learning network includes a plurality of sequential encoder down-sampling blocks. A processor is configured to execute the computer-executable instructions to receive a multi-dimensional input tensor including at least a first dimension, a second dimension and a plurality of channels. The processor is also configured to process the received multi-dimensional input tensor by passing the received multi-dimensional input tensor through the plurality of sequential encoder down-sampling blocks of the learning network, and to generate an output tensor in response to processing the received multi-dimensional input tensor. The output tensor includes at least one segmentation classification.
G06F 18/21 - Conception ou mise en place de systèmes ou de techniquesExtraction de caractéristiques dans l'espace des caractéristiquesSéparation aveugle de sources
G06F 18/211 - Sélection du sous-ensemble de caractéristiques le plus significatif
G06F 18/241 - Techniques de classification relatives au modèle de classification, p. ex. approches paramétriques ou non paramétriques
G06N 3/084 - Rétropropagation, p. ex. suivant l’algorithme du gradient
G06N 5/046 - Inférence en avantSystèmes de production
Methods for rapidly confirming production of infectious viral vectors, for use in clinical grade personalized neo-antigen vaccines for subjects in need thereof, are provided.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present invention relates to a pharmaceutical composition comprising aldoxorubicin HCl and ifosfamide and a method of treating soft tissue sarcoma with a therapeutically effective amount of the pharmaceutical composition.
A61K 31/17 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine
A61K 31/185 - AcidesLeurs anhydrides, halogénures ou sels, p. ex. acides du soufre, acides imidiques, hydrazoniques ou hydroximiques
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.
Contemplated cancer therapies comprise co-administration of aldoxorubicin with an immune therapeutic composition that preferably comprises a vaccine component and a cytotoxic cell component.
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Compositions and methods are provided to treat and prevent cancers, such as myelomas, and include adoptive cell therapies in combination with an IL-15 superagonist and one or more chemotherapeutic agents.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
85.
NEOEPITOPE VACCINE AND IMMUNE STIMULANT COMBINATIONS AND METHODS
Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ prime-boost vaccination in combination with immune modulatory treatment and biasing of an immune response towards a Th1 profile.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
An IL-15 super agonist (IL-15N72D:IL-15RαSU/IgG1Fc; N-803) increases circulating NK cells, effector memory and effector memory RA cells in post-allogeneic hematopoietic stem cell transplant patients (HCT). Methods of treatment include administration of N-803 to subjects in need of such treatment.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A cancer vaccine is provided including a recombinant nucleic acid encoding a self-activating chimeric signaling protein, and especially chimeric TNF family ligand-receptor proteins, and a tumor-associated antigen. In a preferred embodiment, the cancer vaccine may further include a nucleic acid segment encoding an IL-15 superagonist. In addition, the cancer vaccine can be co-administered with a genetically modified bacteria or yeast as an adjuvant to increase the payload expression of the cancer vaccine. Advantageously, cells expressing such combination of molecules will enhance immune reaction against tumor cells. Compositions and methods are presented that allow for an enhanced immune response against a vaccine composition, and particularly a recombinant adenoviral expression system that is used as a therapeutic agent. Most preferably, immune therapeutics are administered such that a protein or nucleotide are co-located with a therapeutic antigen, preferably via co-expression of the protein.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
The present invention includes a method and related compositions to modulate myeloid-derived suppressor cell (MDSC) suppressive function, MDSC differentiation, or combinations thereof in a cancer patient by administering a yeast comprising β-glucans to the cancer patient, in which the yeast can be modified to unmask yeast cell wall β- glucans to enhance the effect on MDSCs.
The present disclosure relates generally to methods for detecting and/or treating cancer by assessing circulating free nucleic acids derived from a bodily fluid sample. In particular, in some embodiments, the disclosed methods involve assessing sequence alteration and/or a fragment-size alteration within microsatellite short tandem repeats which are characteristic to certain cancers and some other health conditions.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate recombinant nucleic acids that encode one or more polytopes that are optimized for proper trafficking and processing. In preferred methods, the polytopes are encoded in a plasmid and/or a viral expression system for use as a therapeutic agent.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ a combination vaccination together with immune modulatory treatment and biasing of an immune response towards a Th1 profile.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Detection of under-expression of selected genes in NK cells is used to confirm a hypoxic tumor microenvironment that is ordinarily suppressive with respect to ADCC and cytotoxic cell killing of NK cells. Most notably, while hypoxia is known to upregulate HIF-1α and genes under the control of HIF-1α, hypoxia in a tumor microenvironment led to under-expression of selected genes, including HIF-1α. Thus, gene expression analysis of certain genes on NK cells can be used to detect conditions in a tumor that would indicate use of haNK cells.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
93.
ANTIBODY-DEPENDENT CELL-MEDIATED TOXICITY MEDIATED BY ALT-803 AND NEO-201
Compositions, methods, and uses are contemplated in which immune competent cells are (pre)treated with an IL-15 superagonist molecule and in which such cells are administered with a neoantigen antibody (especially NEO-201). Such compositions exhibit superior ADCC activity of immune competent cells that can be used in the treatment of cancer.
Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ prime-boost vaccination in combination with immune modulatory treatment and biasing of an immune response towards a Th1 profile.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered.
HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07H 15/04 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'oxygène d'un radical saccharide
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/4406 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 3, p. ex. zimeldine
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations for the prevention, diagnosis, and treatment of cancer; pharmaceutical preparations for immunotherapy treatment; medical and clinical diagnostic kits consisting primarily of cells for diagnostic purposes.
(2) Pharmaceutical preparations for the treatment of infectious disease, namely HIV, for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations for the prevention, diagnosis, and treatment of infectious disease namely HIV; pharmaceutical preparations for the treatment of HIV for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations for the prevention, diagnosis, and treatment of HIV.
The inventors unexpectedly discovered that aldoxorubicin lacks cardio toxicity in patients treated with aldoxorubicin alone or in combination with ifosfamide/mesna. Notably, no evidence of cardiac toxicity of aldoxorubicin was found, even at doxorubicin equivalent cumulative doses of up to 10,000 mg/m2.
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations for the prevention, diagnosis, and treatment of cancer; pharmaceutical preparations for immunotherapy treatment; diagnostic kits consisting primarily of cells for medical or clinical use; pharmaceutical preparations for the treatment of infectious disease for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations for the prevention, diagnosis, and treatment of infectious disease; pharmaceutical preparations for the treatment of HIV for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations for the prevention, diagnosis, and treatment of HIV.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of infectious disease for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations for the prevention, diagnosis, and treatment of infectious disease; pharmaceutical preparations for the treatment of HIV for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations for the prevention, diagnosis, and treatment of HIV
